Experience of using genetically engineered biological therapy in the treatment of chronic urticaria
DOI: 10.32364/2587-6821-2025-9-2-2
E.A. Sobko1,2, I.V. Demko1,2, A.Yu. Kraposhina1,2, V.A. Chernykh1,2
1Prof. V.F. Voino-Yasenetsky Krasnoyarsk State Medical University, Krasnoyarsk, Russian Federation
2Krasnoyarsk Regional Clinical Hospital, Krasnoyarsk, Russian Federation
Background: сhronic spontaneous urticaria (CSU) constitutes a socially significant disease not only due to its high prevalence but also because it predominantly affects individuals of working age, incurs substantial financial costs for treatment, and exhibits the absence of standardized diagnostic and therapeutic protocols.
Aim: to analyze clinical experience in achieving remission or disease control in patients with severe CSU through the use of omalizumab.
Materials and Methods: the study enrolled 30 patients, including 8 males, with a median age of 48 years [33; 55] and a median disease onset of 32 years [20.5; 40.75] (with a disease duration of over 12 months). Urticaria symptom severity was assessed using the UAS-7 questionnaire at baseline and throughout the follow-up period.
Results: patients were initially treated with double doses of second-generation antihistamines and systemic corticosteroids (as needed), without achieving significant symptom improvement. At the initiation of omalizumab therapy, the median UAS-7 score was 41 points [35,25; 42]. Treatment with omalizumab resulted in partial or complete disease control, the discontinuation of systemic glucocorticosteroids, and partial or complete withdrawal of second-generation antihistamines. Early clinical remission was achieved in 40% of patients, while 50% exhibited a delayed response, with a substantial reduction in urticaria activity occurring after eight weeks of treatment.
Conclusion: the results of this study underscore the high efficacy of omalizumab as a targeted immunobiological therapy in patients with severe CSU.
Keywords: chronic spontaneous urticaria, chronic induced urticaria, antihistamines, omalizumab, therapy efficacy.
For citation: Sobko E.A., Demko I.V., Kraposhina A.Yu., Chernykh V.A. Experience of using genetically engineered biological therapy in the treatment of chronic urticaria. Russian Medical Inquiry. 2025;9(2):105–111 (in Russ.). DOI: 10.32364/2587-6821-2025-9-2-2
About the authors:
Elena A. Sobko — Dr. Sc. (Med.), Professor of Department of Hospital Therapy and Immunology with Postgraduate Education course, Prof. V.F. Voino-Yasenetsky Krasnoyarsk State Medical University; 1, Partizan Zheleznyak str., Krasnoyarsk, 660022, Russian Federation; Head of the Department of Allergology, Krasnoyarsk Regional Clinical Hospital; 3A, Partizan Zheleznyak str., Krasnoyarsk, 660022, Russian Federation; ORCID iD 0000-0002-9377-5213
Irina V. Demko — Dr. Sc. (Med.), Professor, Head of the Department of Hospital Therapy and Immunology with Postgraduate Education course, Prof. V.F. Voino-Yasenetsky Krasnoyarsk State Medical University; 1, Partizan Zheleznyak str., Krasnoyarsk, 660022, Russian Federation; Head of the Pulmonary and Allergy Center, Krasnoyarsk Regional Clinical Hospital; 3A, Partizan Zheleznyak str., Krasnoyarsk, 660022, Russian Federation; ORCID iD 0000-0001-8982-5292
Angelina Yu. Kraposhina — C. Sc. (Med.), Associate Professor of the Department of Hospital Therapy and Immunology with Postgraduate Education course, Prof.
V.F. Voino-Yasenetsky Krasnoyarsk State Medical University; 1, Partizan Zheleznyak str., Krasnoyarsk, 660022, Russian Federation; pulmonologist of the Department of Pulmonology, Krasnoyarsk Regional Clinical Hospital; 3A, Partizan Zheleznyak str., Krasnoyarsk, 660022, Russian Federation; ORCID iD 0000-0001-6896-877X
Victoria A. Chernykh — Assistant Professor of the Department of Hospital Therapy and Immunology with Postgraduate Education course, Prof. V.F. Voino-Yasenetsky Krasnoyarsk State Medical University; 1,
Partizan Zheleznyak str., Krasnoyarsk, 660022, Russian Federation; allergologist-immunologist of the Department
of Allergology, Krasnoyarsk Regional Clinical Hospital; 3A, Partizan Zheleznyak str., Krasnoyarsk, 660022, Russian Federation; ORCID iD 0009-0003-9191-5475
Contact information: Angelina Yu. Kraposhina, e-mail: angelina-maria@inbox.ru
Financial Disclosure: no authors have a financial or property interest in any material or method mentioned.
There is no conflict of interest.
Received 05.02.2025.
Revised 28.02.2025.
Accepted 25.03.2025.
2. Dias G.A.C., Coelho F.C., Pennaforte C. et al. Quality of life and disease activity assessment in patients with chronic urticaria. World Allergy Organ J. 2015;8(Suppl 1):A91. DOI: 10.1186/1939-4551-8-S1-A91
3. Schaefer P. Acute and Chronic Urticaria: Evaluation and Treatment. Am Fam Physician. 2017;95(11):717–724. PMID: 28671445
4. Pluta-Kubicz M., Brzoza Z. Chronic Urticaria — Pathogenesis, Diagnostics, Therapy and Influence of Coexisting Angioedema. J Clin Med. 2023;12(2):688. DOI: 10.3390/jcm12020688
5. Zuberbier T., Aberer W., Asero R. et al. The EAACI/GA2LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of Urticaria. The 2017 revision and update. Allergy. 2018;73:1393–1414. DOI: 10.1111/all.13397
6. Ильина Н.И., Данилычева И.В., Дорофеева И.В. и др. Хроническая крапивница в теории и практике. Опыт UCARE-центров — практическим врачам. Российский аллергологический журнал. 2021;18(1):79–96. DOI: 10.36691/RJA1425Il'ina N.I., Danilycheva I.V., Dorofeeva I.V. et al. Chronic urticaria in theory and practice. Experience of UCARE centers — practical doctors. Russian Allergological Journal. 2021;18(1):79–96 (in Russ.). DOI: 10.36691/RJA1425
7. Gu S.L., Jorizzo J.L. Urticarial vasculitis. Int J Womens Dermatol. 2021;7:290–297. DOI: 10.1016/j.ijwd.2021.01.021
8. Sirufo M.M., Ginaldi L., De Martinis M. Successful Treatment With Omalizumab in a Child With Asthma and Urticaria: A Clinical Case Report. Front Pediatr. 2019;7:213. DOI: 10.3389/fped.2019.00213
9. Bindslev-Jensen C., Skov P.S. Efficacy of omalizumab in delayed pressure urticaria: a case report. Allergy. 2010;65(1):138–139. DOI: 10.1111/j.1398-9995.2009.02188.x
10. Boyce J.A. Successful treatment of cold-induced urticaria/ anaphylaxis with anti-IgE. J Allergy Clin Immunol. 2006;117(6):1415–1418. DOI: 10.1016/j.jaci.2006.04.003
11. Metz M., Altrichter S., Ardelean E. et al. Anti-immunoglobulin E treatment of patients with recalcitrant physical urticarial. Allergy Immunol. 2011;154(2):177–180. DOI: 10.1159/000320233
12. Saini S., Rosen K.E., Hsieh H.J. et al. A randomized, placebocontrolled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticarial. Allergy Clin Immunol. 2011;128(3):567–573. DOI: 10.1016/j.jaci.2011.06.010
13. Maurer M., Altrichter S., Bieber T. et al. Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase. J Allergy Clin Immunol. 2011;128(1):202–209. e205. DOI: 10.1016/j.jaci.2011.04.038
14. Durack A., Matin R.N. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria: a critical appraisal. Br J Dermatol. 2014;171(1):10–13. DOI: 10.1111/bjd.13073
15. Kaplan A., Ledford D., Ashby M. et al. Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy. J Allergy Clin Immunol. 2013;132(1):101–109. DOI: 10.1016/j.jaci.2013.05.013
16. Sussman G., Hébert J., Barron C. et al. Real-life experiences with omalizumab for the treatment of chronic urticarial. Ann Allergy Asthma Immunol. 2014;112(2):170–174. DOI: 10.1016/j.anai.2013.12.005
17. Ненашева Н.М., Аверьянов А.В., Ильина Н.И. и др. Сравнительное изучение клинической эффективности биоаналогичного препарата Генолар® по результатам рандомизированного клинического исследования III фазы. Пульмонология. 2020;30(6):782–796. DOI: 10.18093/0869-0189-2020-30-6-782-796Nenasheva N.M., Aver'yanov A.V., Il'ina N.I. et al. A comparative study of the clinical efficacy of the biosimilar drug Genolar® based on the results of a randomized phase III clinical trial. Pulmonology. 2020;30(6):782–796 (in Russ.). DOI: 10.18093/0869-0189-2020-30-6-782-796
18. Переверзина Н.О., Круглова Л.С., Мусаев И.Э. Настоящее и будущее в терапии хронической спонтанной крапивницы. Клиническая дерматология и венерология. 2020;19(5):604–612. DOI: 10.17116/klinderma202019051604Pereverzina N.O., Kruglova L.S., Musaev I.E. Present and future in the treatment of chronic spontaneous urticaria. Russian Journal of Clinical Dermatology and Venereology. 2020;19(5):604–612 (in Russ.). DOI: 10.17116/klinderma202019051604
19. Kaplan A.P., Giménez-Arnau A.M., Saini S.S. Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticarial. Allergy. 2017;72(4):519–533. DOI: 10.1111/all.13083
20. Rubinia N.P.M., Ensinab L.F.C., Silvac E.M.K. et al. Effectiveness and safety of Omalizumab in the treatment of chronic spontaneous urticaria: Systematic review and meta-analysis. Allergologia et Immunopathologia. 2019;47(6):515–522. DOI: 10.1016/j.aller.2019.05.003
21. Олисова О.Ю., Скандер Д.М. Омализумаб в терапии различных форм хронической крапивницы. Российский журнал кожных и венерических болезней. 2023;26(3):243–250. DOI: 10.17816/dv321359Olisova O.Yu., Skander D.M. Omalizumab in the treatment of various forms of chronic urticaria. Russian Journal of Skin and Sexually Transmitted Diseases. 2023;26(3):243–250 (in Russ.). DOI: 10.17816/dv321359
22. Собко Е.А., Демко И.В., Шестакова Н.А. и др. Опыт продолжительного использования анти-IgE-терапии у пациентки с хронической спонтанной крапивницей. Медицинский совет. 2022;(6):176–180. DOI: 10.21518/2079-701X-2022-16-6-176-180Sobko E.A., Demko I.V., Shestakova N.A. et al. Experience of long-term use of anti-IgE therapy in a patient with chronic spontaneous urticarial. Medical Council. 2022;(6):176–180 (in Russ.). DOI: 10.21518/2079-701X-2022-16-6-176-180
23. Шульженко А.Е., Сорокина Л.Е., Ковалькова Е.В. и др. Сравнительный анализ клинической эффективности и безопасности биоаналога омализумаба в лечении пациентов с хронической спонтанной крапивницей. Российский аллергологический журнал. 2023;20(3):309–320. DOI: 10.36691/RJA15046Shulzhenko A.E, Sorokina L.E, Kovalkova E.V. et al. Comparative analysis of clinical efficacy and safety of omalizumab biosimilar in the treatment of patients with chronic spontaneous urticaria. Russian Journal of Allergy. 2023;20(3):309–320 (in Russ.). DOI: 10.36691/RJA15046
This work is licensed under a Creative Commons «Attribution» 4.0 License.
Распечатать